肾性贫血腹膜透析患者骨化三醇治疗后铁代谢水平

The Level of Iron Metabolism after Calcitriol Treatment in Patients with Renal Anemia Undergoing Peritoneal Dialysis

目的观察肾性贫血腹膜透析患者骨化三醇治疗后铁代谢水平。方法选取2019年3月-2021年9月我院收治的60例肾性贫血腹膜透析患者,将其随机分为观察组和对照组,每组各30例。对照组采取常规重组人促红细胞生长素注射治疗,观察组在对照组的基础上服用骨化三醇。比较两组血红蛋白(Hb)、红细胞计数(RBC)、血清铁调素(Hepcidin)、血清铁(SI)、血清铁蛋白(SF)水平,并统计两组不良反应发生率。结果与治疗前及对照组治疗后比较,观察组治疗后Hb、RBC水平显著增高(P<0.05)。与治疗前及对照组治疗后比较,观察组治疗后Hepcidin、SF水平显著降低,SI水平显著增高(P<0.05)。两组不良反应发生率比较,差异不具有显著性(P>0.05)。结论骨化三醇治疗可显著改善肾性贫血患者铁代谢水平,临床价值较高。

Objective:To observe the level of iron metabolism in renal anemia patients undergoing peritoneal dialysis after calcitriol treatment.Methods:60 patients with renal anemia undergoing peritoneal dialysis from March2019 to September 2021 in our hospital were selected,and were randomly divided into observation group and control group,with 30 cases in each group.The control group was treated with conventional injection of recombinant human erythropoietin,while the observation group was treated with calcitriol on the basis of the control group.The levels of hemoglobin(Hb),red blood cell count(RBC),serum Hepcidin,serum iron(SI)and serum ferritin(SF)were compared between the two groups,and the incidence of adverse reactions was counted between the two groups.Results:Compared with before treatment and after treatment in the control group,the levels of Hb and RBC in the observation group increased significantly after treatment(P<0.05).Compared with before treatment and after treatment in the control group,the levels of Hepcidin and SF in the observation group decreased significantly,while the level of SI increased significantly(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Calcitonol treatment can significantly improve the level of iron metabolism in patients with renal anemia,which is of high clinical value.